XML 24 R9.htm IDEA: XBRL DOCUMENT v3.19.1
PRODUCT REVENUE (Notes)
 9 Months Ended
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]  
PRODUCT REVENUE
PRODUCT REVENUE
Our commercial stage products include BRAFTOVI + MEKTOVI, which received FDA approval on June 27, 2018 as a combination therapy for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.

We record gross-to-net sales accruals for rebates, chargebacks, discounts, estimated product returns and other allowances that are offered within contracts between us and our Customers and other indirect customers relating to the sales of our products.

Our provisions for discounts, early payments, rebates, sales returns, distributor service fees and chargebacks, and other incentives are under terms that are customary in the industry and are provided for in the same period in which the related sales are recorded.

Net product revenue by product for the three and nine months ended March 31, 2019 was as follows (in thousands):
 
 
Three Months Ended
March 31, 2019
 
Nine Months Ended
March 31, 2019
BRAFTOVI
 
$
17,351

 
$
35,737

MEKTOVI
 
17,727

 
36,047

Total net product sales
 
$
35,078

 
$
71,784



Gross-to-net sales accruals and the balance in the related allowance accounts for the nine months ended March 31, 2019 were as follows (in thousands):
 
 
Returns
Other
Total
Balance as of June 30, 2018
 
$
—

$
—

$
—

Allowances for sales during prior periods
 
—

—

—

Allowances for sales during the current period
 
129

14,592

14,721

Credits/deductions issued for prior year sales
 
—

—

—

Credits/deductions issued for sales during the current period
 
(26
)
(9,507
)
(9,533
)
Balance as of March 31, 2019
 
$
103

$
5,085

$
5,188



There were no product sales or gross-to-net accruals during the three and nine months ended March 31, 2018.